Endostar Combination With Chemotherapy and EGFR-TKI in Lung Cancer Rechallenging Treatment After Acquired Resistance.

NCT02350361 · clinicaltrials.gov ↗

PHASE2,PHASE3

Phase

UNKNOWN

Status

60

Enrollment

OTHER

Sponsor class

Conditions

Lung Cancer

Interventions

DRUG: Recombinant human endostatin
DRUG: Placebo

Sponsor

Peking University Third Hospital